• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

防治全身糖皮质激素副作用。

Prevention and treatment of systemic glucocorticoid side effects.

机构信息

Philadelphia VA Hospital, Philadelphia, PA, USA.

出版信息

Int J Dermatol. 2010 Mar;49(3):239-48. doi: 10.1111/j.1365-4632.2009.04322.x.

DOI:10.1111/j.1365-4632.2009.04322.x
PMID:20465658
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2872100/
Abstract

BACKGROUND

Systemic glucocorticoids are used in dermatologic practice for various diseases including connective tissue disorders, bullous diseases, and many other dermatologic conditions. Patients with these diseases are at times treated with long-term courses of glucocorticoids, which place them at increased risk for glucocorticoid-induced side effects. Therefore, dermatologists must be knowledgeable of risks related to glucocorticoid use and be familiar with guidelines to manage them.

OBJECTIVE

To provide an update of recent advances in the prevention and treatment of major glucocorticoid-induced side effects.

METHODS

Review of the literature.

RESULTS

Data regarding the prevention and treatment of glucocorticoid-induced side effects are presented.

CONCLUSION

This review should help dermatologists optimally manage and prevent glucocorticoid-induced side effects.

摘要

背景

在皮肤科实践中,全身性糖皮质激素被用于各种疾病,包括结缔组织疾病、大疱性疾病以及许多其他皮肤科疾病。这些疾病的患者有时需要接受长期的糖皮质激素治疗,这使他们面临糖皮质激素诱导的副作用的风险增加。因此,皮肤科医生必须了解与糖皮质激素使用相关的风险,并熟悉管理这些风险的指南。

目的

提供糖皮质激素诱导的主要副作用的预防和治疗的最新进展。

方法

文献复习。

结果

提出了关于预防和治疗糖皮质激素诱导的副作用的数据。

结论

本综述应有助于皮肤科医生优化管理和预防糖皮质激素诱导的副作用。

相似文献

1
Prevention and treatment of systemic glucocorticoid side effects.防治全身糖皮质激素副作用。
Int J Dermatol. 2010 Mar;49(3):239-48. doi: 10.1111/j.1365-4632.2009.04322.x.
2
Prevention and treatment of glucocorticoid-induced osteoporosis in daily dermatologic practice.日常皮肤科实践中糖皮质激素诱导性骨质疏松症的防治
Int J Dermatol. 2008 Jul;47(7):737-42. doi: 10.1111/j.1365-4632.2008.03679.x.
3
Suggested rationale for prevention and treatment of glucocorticoid-induced bone loss in dermatologic patients.皮肤病患者糖皮质激素性骨丢失预防与治疗的建议理论依据。
Arch Dermatol. 2001 Apr;137(4):477-81.
4
Systemic glucocorticoids: important issues and practical guidelines for the dermatologist.全身性糖皮质激素:皮肤科医生的重要问题及实用指南
Int J Dermatol. 2015 Jun;54(6):723-9. doi: 10.1111/ijd.12642. Epub 2015 Feb 13.
5
Glucocorticoid-induced bone loss in dermatologic patients: an update.皮肤科患者糖皮质激素诱导的骨质流失:最新进展
Arch Dermatol. 2006 Jan;142(1):82-90. doi: 10.1001/archderm.142.1.82.
6
Preventive techniques to limit glucocorticoid-induced side effects.限制糖皮质激素诱导副作用的预防技术。
Adv Dermatol. 2000;16:273-97; discussion 298.
7
Systemic glucocorticoid therapy: a review of its metabolic and cardiovascular adverse events.全身糖皮质激素治疗:代谢和心血管不良事件综述。
Drugs. 2014 Oct;74(15):1731-45. doi: 10.1007/s40265-014-0282-9.
8
Corticosteroids: a review with emphasis on complications of prolonged systemic therapy.皮质类固醇:一篇重点关注长期全身治疗并发症的综述
Ann Allergy. 1989 May;62(5):375-91.
9
Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis.糖皮质激素性骨质疏松症的预防和治疗建议:2001年更新版。美国风湿病学会糖皮质激素性骨质疏松症特别委员会
Arthritis Rheum. 2001 Jul;44(7):1496-503. doi: 10.1002/1529-0131(200107)44:7<1496::AID-ART271>3.0.CO;2-5.
10
Prevention and treatment of glucocorticoid-induced osteoporosis. A pathogenetic perspective.
Chest. 1992 Nov;102(5):1426-35. doi: 10.1378/chest.102.5.1426.

引用本文的文献

1
Protective Efficacy of Postbiotic beLP-K in a Dexamethasone-Induced Sarcopenia Model.后生元beLP-K在地塞米松诱导的肌肉减少症模型中的保护作用
Int J Mol Sci. 2025 Aug 3;26(15):7504. doi: 10.3390/ijms26157504.
2
Emerging therapeutic approaches in graves' ophthalmopathy: an update on pharmacological interventions.格雷夫斯眼病的新兴治疗方法:药物干预的最新进展
Front Immunol. 2025 Jul 25;16:1647602. doi: 10.3389/fimmu.2025.1647602. eCollection 2025.
3
Cost per Response of Acthar® Gel vs Standard of Care for the Treatment of Proteinuria in Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy Among Adults from the US Healthcare Perspective.从美国医疗保健角度看,Acthar®凝胶与标准治疗方案治疗成人特发性膜性肾病所致肾病综合征蛋白尿的每反应成本。
J Health Econ Outcomes Res. 2025 Aug 6;12(2):50-61. doi: 10.36469/001c.142078. eCollection 2025.
4
Efficacy of WuSheZhiYang Pills in Mild-to-Moderate Atopic Dermatitis: Protocol for a Double-Blind, Randomized, Placebo-Controlled Trial.乌蛇止痒丸治疗轻至中度特应性皮炎的疗效:一项双盲、随机、安慰剂对照试验方案
JMIR Res Protoc. 2025 Jul 2;14:e77927. doi: 10.2196/77927.
5
Evaluating TnP as a Potential Therapeutic Agent for Retinopathy in Zebrafish Models.评估TnP作为斑马鱼模型中视网膜病变潜在治疗剂的作用。
Pharmaceuticals (Basel). 2025 Jun 4;18(6):840. doi: 10.3390/ph18060840.
6
Physical Activity and Sedentary Time Correlate with Body Composition in Patients with Asthma; a Multicenter Observational Study.体力活动和久坐时间与哮喘患者的身体成分相关;一项多中心观察性研究。
J Asthma Allergy. 2025 May 28;18:835-846. doi: 10.2147/JAA.S514541. eCollection 2025.
7
Emerging role of Rituximab in adult minimal change disease: a narrative review of clinical evidence, biomarkers and future perspectives.利妥昔单抗在成人微小病变病中的新作用:临床证据、生物标志物及未来展望的叙述性综述
BMC Nephrol. 2025 Mar 26;26(1):152. doi: 10.1186/s12882-025-04086-3.
8
Enhanced epigenetic modulation via mRNA-encapsulated lipid nanoparticles enables targeted anti-inflammatory control.通过mRNA包裹的脂质纳米颗粒增强表观遗传调控可实现靶向抗炎控制。
bioRxiv. 2025 Feb 28:2025.02.24.639996. doi: 10.1101/2025.02.24.639996.
9
Cancer treatment-related xerostomia: basics, therapeutics, and future perspectives.癌症治疗相关的口干症:基础、治疗和未来展望。
Eur J Med Res. 2024 Nov 30;29(1):571. doi: 10.1186/s40001-024-02167-x.
10
Appraisal terpenoids rich Boswellia carterri ethyl acetate extract in binary cyclodextrin oligomer nano complex for improving respiratory distress.评价富含倍半萜的 Boswellia carterri 乙酸乙酯提取物在二元环糊精寡聚物纳米复合物中对改善呼吸窘迫的作用。
Sci Rep. 2024 Jul 22;14(1):16779. doi: 10.1038/s41598-024-66297-2.

本文引用的文献

1
Prevention and treatment of glucocorticoid-induced osteoporosis in daily dermatologic practice.日常皮肤科实践中糖皮质激素诱导性骨质疏松症的防治
Int J Dermatol. 2008 Jul;47(7):737-42. doi: 10.1111/j.1365-4632.2008.03679.x.
2
Glucocorticoids differentially regulate degradation of MyoD and Id1 by N-terminal ubiquitination to promote muscle protein catabolism.糖皮质激素通过N端泛素化差异调节MyoD和Id1的降解,以促进肌肉蛋白质分解代谢。
Proc Natl Acad Sci U S A. 2008 Mar 4;105(9):3339-44. doi: 10.1073/pnas.0800165105. Epub 2008 Feb 22.
3
Teriparatide or alendronate in glucocorticoid-induced osteoporosis.特立帕肽或阿仑膦酸钠用于糖皮质激素诱导的骨质疏松症
N Engl J Med. 2007 Nov 15;357(20):2028-39. doi: 10.1056/NEJMoa071408.
4
Risedronate, an effective treatment for glucocorticoid-induced bone loss in CKD patients with or without concomitant active vitamin D (PRIUS-CKD).利塞膦酸盐,对伴有或不伴有活性维生素D的慢性肾脏病患者糖皮质激素诱导的骨质流失有效(PRIUS-CKD)。
Nephrol Dial Transplant. 2007 Jun;22(6):1601-7. doi: 10.1093/ndt/gfl567. Epub 2006 Nov 23.
5
Effect of risedronate on high-dose corticosteroid-induced bone loss in patients with glomerular disease.利塞膦酸盐对肾小球疾病患者高剂量糖皮质激素所致骨质流失的影响。
Nephrol Dial Transplant. 2007 Jun;22(6):1593-600. doi: 10.1093/ndt/gfl568. Epub 2006 Oct 13.
6
Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis.阿仑膦酸钠或阿法骨化醇治疗糖皮质激素诱导的骨质疏松症。
N Engl J Med. 2006 Aug 17;355(7):675-84. doi: 10.1056/NEJMoa053569.
7
Glucocorticoid use and serum lipid levels in US adults: the Third National Health and Nutrition Examination Survey.美国成年人中糖皮质激素的使用与血脂水平:第三次全国健康与营养检查调查
Arthritis Rheum. 2005 Aug 15;53(4):528-35. doi: 10.1002/art.21329.
8
Neuromuscular sequelae of critical illness.危重病的神经肌肉后遗症
Curr Opin Crit Care. 2005 Aug;11(4):381-90. doi: 10.1097/01.ccx.0000168530.30702.3e.
9
Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease.按处方服用糖皮质激素与随后发生的心血管疾病有关。
Ann Intern Med. 2004 Nov 16;141(10):764-70. doi: 10.7326/0003-4819-141-10-200411160-00007.
10
Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study.基于人群的病例对照研究中口服糖皮质激素的使用与心血管和脑血管疾病风险
Heart. 2004 Aug;90(8):859-65. doi: 10.1136/hrt.2003.020180.